| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Cerebral dopamine neurotrophic factor (ARMET-like protein 1; Conserved dopamine neurotrophic factor) |
| Entrez GeneID | 441549 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide from human protein at AA range: 31-80 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇与CDNF(Cerebral Dopamine Neurotrophic Factor)抗体相关的文献概览：
1. **文献名称**：*Cerebral Dopamine Neurotrophic Factor Protects and Repairs Dopamine Neurons by Novel Mechanism*
**作者**：Lindholm, P. et al.
**摘要**：该研究揭示了CDNF通过调节内质网应激通路对多巴胺能神经元发挥神经保护作用，并开发了特异性CDNF抗体用于检测其在帕金森病模型中的表达分布。
2. **文献名称**：*Antibody-Based Validation of CNS-Related Therapeutic Targets: CDNF as a Case Study*
**作者**：Huttunen, H.J. & Saarma, M.
**摘要**：文章系统评估了CDNF抗体的特异性与敏感性，验证了其在脑脊液及脑组织中的检测效能，为CDNF作为帕金森病治疗标志物提供技术支持。
3. **文献名称**：*CDNF Antibodies Modulate Neuroprotection in a Rotenone-Induced Parkinson’s Model*
**作者**：Airavaara, M. et al.
**摘要**：通过使用中和性CDNF抗体阻断内源性CDNF功能，研究证实CDNF缺失加剧黑质神经元退化，反向验证了其治疗帕金森病的潜在机制。
注：以上信息综合了CDNF抗体在机制研究、检测技术验证及疾病模型中的应用场景，文献标题与作者为模拟示例，实际引用需以具体数据库检索结果为准。
CDNF (Cerebral Dopamine Neurotrophic Factor) is a secreted protein belonging to the evolutionarily conserved MANF/CDNF family, initially identified for its neuroprotective effects on dopaminergic neurons. Unlike classical neurotrophic factors, CDNF and its homolog MANF (Mesencephalic Astrocyte-derived Neurotrophic Factor) exhibit dual functionality: they act as extracellular signaling molecules supporting neuronal survival and as intracellular chaperones mitigating endoplasmic reticulum (ER) stress. CDNF is particularly implicated in neurodegenerative disorders, such as Parkinson’s disease (PD), where its loss correlates with dopaminergic degeneration. Preclinical studies demonstrate that CDNF administration rescues neuronal function in PD models, prompting clinical trials for intra-brain delivery.
CDNF antibodies are critical tools for detecting and quantifying endogenous CDNF expression, elucidating its tissue distribution, and validating therapeutic efficacy in experimental models. These antibodies enable researchers to study CDNF’s dynamic regulation under pathological conditions, including ER stress, inflammation, and oxidative damage. Challenges persist in developing high-specificity antibodies due to CDNF’s structural similarity to MANF and low basal expression levels in most tissues. Recent advances in recombinant protein production and epitope mapping have improved antibody reliability, facilitating mechanistic studies and biomarker development. CDNF-targeted therapies and companion diagnostics remain active areas of research, underscoring the antibody’s role in bridging basic science and translational applications.
×
